Bessemer Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Bessemer Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500	Closed	-$79K	–	1731
2019 Q4	$79K	Buy	+500	New	+$73.8K	﹤0.01%	1210

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bessemer Group's VRCA Position: Q1 2020 in Review

Bessemer Group sold out of Verrica Pharmaceuticals (VRCA) in Q1 2020, closing a stake of 500 shares — an estimated $79K sold.

Bessemer Group first reported a position in VRCA in Q4 2019 and held it in 1 quarter. The position peaked at $79K in Q4 2019. 48 funds tracked by Wall St. Rank hold VRCA as of Q1 2020.

Bessemer Group reported no remaining Verrica Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Bessemer Group sold 500 Verrica Pharmaceuticals shares in Q1 2020, an estimated $79K.
Bessemer Group first reported a position in Verrica Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Bessemer Group's Verrica Pharmaceuticals position peaked at $79K in Q4 2019.
48 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2020.

Based on Bessemer Group's 13F filing for Q1 2020, filed 30 Apr 2020.